

# Renata Silva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2376697/publications.pdf>

Version: 2024-02-01

76  
papers

2,504  
citations

186265

28  
h-index

243625

44  
g-index

99  
all docs

99  
docs citations

99  
times ranked

3585  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vine Cane Compounds to Prevent Skin Cells Aging through Solid Lipid Nanoparticles. <i>Pharmaceutics</i> , 2022, 14, 240.	4.5	5
2	Stabilization of Silver Nanoparticles on Polyester Fabric Using Organo-Matrices for Controlled Antimicrobial Performance. <i>Polymers</i> , 2022, 14, 1138.	4.5	18
3	Long-term effects of lithium and lithium-microplastic mixtures on the model species <i>Daphnia magna</i> : Toxicological interactions and implications to "One Health". <i>Science of the Total Environment</i> , 2022, 838, 155934.	8.0	14
4	Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform. <i>Ageing Research Reviews</i> , 2022, 79, 101658.	10.9	22
5	Fiscalin Derivatives as Potential Neuroprotective Agents. <i>Pharmaceutics</i> , 2022, 14, 1456.	4.5	3
6	Xanthones as P-glycoprotein modulators and their impact on drug bioavailability. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 441-482.	3.3	9
7	S-(+)-Pentedrone and R-(+)-methyline as the most oxidative and cytotoxic enantiomers to dopaminergic SH-SY5Y cells: Role of MRP1 and P-gp in cathinones enantioselectivity. <i>Toxicology and Applied Pharmacology</i> , 2021, 416, 115442.	2.8	8
8	Design and characterization of Nanostructured lipid carriers (NLC) and Nanostructured lipid carrier-based hydrogels containing <i>Passiflora edulis</i> seeds oil. <i>International Journal of Pharmaceutics</i> , 2021, 600, 120444.	5.2	28
9	Antimicrobial Activity of a Library of Thioxanthenes and Their Potential as Efflux Pump Inhibitors. <i>Pharmaceutics</i> , 2021, 14, 572.	3.8	11
10	Mapping Chromone-3-Phenylcarboxamide Pharmacophore: <i>Quid Est Veritas</i> ?. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11169-11182.	6.4	9
11	In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN). <i>Pharmaceutics</i> , 2021, 14, 711.	3.8	37
12	Quality by design (QbD) optimization of diazepam-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery: Toxicological effect of surface charge on human neuronal cells. <i>International Journal of Pharmaceutics</i> , 2021, 607, 120933.	5.2	16
13	Lipid Nanoparticles Containing Mixtures of Antioxidants to Improve Skin Care and Cancer Prevention. <i>Pharmaceutics</i> , 2021, 13, 2042.	4.5	12
14	Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies. <i>European Journal of Medicinal Chemistry</i> , 2020, 185, 111770.	5.5	30
15	P-glycoprotein activation by 1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one (TX5) in rat distal ileum: ex vivo and in vivo studies. <i>Toxicology and Applied Pharmacology</i> , 2020, 386, 114832.	2.8	3
16	Pessaries containing nanostructured lipid carriers (NLC) for prolonged vaginal delivery of progesterone. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 153, 105475.	4.0	12
17	Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease. <i>Pharmaceutics</i> , 2020, 13, 242.	3.8	29
18	New marine-derived indolymethyl pyrazinoquinazoline alkaloids with promising antimicrobial profiles. <i>RSC Advances</i> , 2020, 10, 31187-31204.	3.6	7

#	ARTICLE	IF	CITATIONS
19	Oxygenated xanthenes as P-glycoprotein modulators at the intestinal barrier: in vitro and docking studies. <i>Medicinal Chemistry Research</i> , 2020, 29, 1041-1057.	2.4	9
20	Enantioselectivity on the absorption of methylone and pentedrone using Caco-2 cell line: Development and validation of an UHPLC method for cathinones quantification. <i>Toxicology and Applied Pharmacology</i> , 2020, 395, 114970.	2.8	9
21	Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. , 2020, 213, 107554.		83
22	Boosting Drug Discovery for Parkinson's: Enhancement of the Delivery of a Monoamine Oxidase-B Inhibitor by Brain-Targeted PEGylated Polycaprolactone-Based Nanoparticles. <i>Pharmaceutics</i> , 2019, 11, 331.	4.5	11
23	Evaluation of the biocompatibility and skin hydration potential of vitamin E-loaded lipid nanosystems formulations: In vitro and human in vivo studies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 179, 242-249.	5.0	33
24	Fine-tuning the neuroprotective and blood-brain barrier permeability profile of multi-target agents designed to prevent progressive mitochondrial dysfunction. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 525-545.	5.5	29
25	Newly Synthesized Oxygenated Xanthenes as Potential P-Glycoprotein Activators: In Vitro, Ex Vivo, and In Silico Studies. <i>Molecules</i> , 2019, 24, 707.	3.8	22
26	The Use of Feathers from Racing Pigeons for Doping Control Purposes. <i>Journal of Analytical Toxicology</i> , 2019, 43, 307-315.	2.8	7
27	Histological and toxicological evaluation, in rat, of a P-glycoprotein inducer and activator: 1-(propan-2-ylamino)-4-propoxy-9-thioxanthen-9-one (TX5). <i>EXCLI Journal</i> , 2019, 18, 697-722.	0.7	2
28	Quantification of doping compounds in faecal samples from racing pigeons, by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1089, 33-42.	2.3	4
29	PEGylated PLGA Nanoparticles As a Smart Carrier to Increase the Cellular Uptake of a Coumarin-Based Monoamine Oxidase B Inhibitor. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 39557-39569.	8.0	37
30	Chiral Thioxanthenes as Modulators of P-glycoprotein: Synthesis and Enantioselectivity Studies. <i>Molecules</i> , 2018, 23, 626.	3.8	17
31	Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen. <i>Pharmaceutical Development and Technology</i> , 2017, 22, 336-349.	2.4	57
32	Characterization and biocompatibility evaluation of cutaneous formulations containing lipid nanoparticles. <i>International Journal of Pharmaceutics</i> , 2017, 519, 373-380.	5.2	37
33	Quantification of 1-(propan-2-ylamino)-4-propoxy-9-thioxanthen-9-one (TX5), a newly synthesized P-glycoprotein inducer/activator, in biological samples: method development and validation. <i>Biomedical Chromatography</i> , 2017, 31, e3802.	1.7	1
34	Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP. <i>Molecules</i> , 2017, 22, 600.	3.8	91
35	Development of mucoadhesive and thermosensitive eyedrops to improve the ophthalmic bioavailability of ibuprofen. <i>Journal of Drug Delivery Science and Technology</i> , 2016, 35, 69-80.	3.0	30
36	3,4-Methylenedioxypropylvalerone (MDPV): in vitro mechanisms of hepatotoxicity under normothermic and hyperthermic conditions. <i>Archives of Toxicology</i> , 2016, 90, 1959-1973.	4.2	62

#	ARTICLE	IF	CITATIONS
37	<i>In vitro</i> neurotoxicity evaluation of piperazine designer drugs in differentiated human neuroblastoma SH-SY5Y cells. Journal of Applied Toxicology, 2016, 36, 121-130.	2.8	30
38	New Thermoresponsive Eyedrop Formulation Containing Ibuprofen Loaded-Nanostructured Lipid Carriers (NLC): Development, Characterization and Biocompatibility Studies. Current Drug Delivery, 2016, 13, 953-970.	1.6	7
39	Induction and activation of P-glycoprotein efflux pump as a therapeutic strategy. Toxicology Letters, 2015, 238, S48.	0.8	0
40	Is hyperthermia the triggering factor for hepatotoxicity induced by "bath salts"™? An in vitro study using primary cultured rat hepatocytes. Toxicology Letters, 2015, 238, S260.	0.8	0
41	Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. , 2015, 149, 1-123.		275
42	Several transport systems contribute to the intestinal uptake of Paraquat, modulating its cytotoxic effects. Toxicology Letters, 2015, 232, 271-283.	0.8	17
43	P-glycoprotein induction in Caco-2 cells by newly synthesized thioxanthenes prevents paraquat cytotoxicity. Archives of Toxicology, 2015, 89, 1783-1800.	4.2	34
44	Piperazine designer drugs induce toxicity in cardiomyoblast h9c2 cells through mitochondrial impairment. Toxicology Letters, 2014, 229, 178-189.	0.8	43
45	RBE4 cells are highly resistant to paraquat-induced cytotoxicity: studies on uptake and efflux mechanisms. Journal of Applied Toxicology, 2014, 34, 1023-1030.	2.8	19
46	Mitochondrial Cumulative Damage Induced by Mitoxantrone: Late Onset Cardiac Energetic Impairment. Cardiovascular Toxicology, 2014, 14, 30-40.	2.7	37
47	"Ecstasy"-induced toxicity in SH-SY5Y differentiated cells: role of hyperthermia and metabolites. Archives of Toxicology, 2014, 88, 515-531.	4.2	29
48	The mixture of "ecstasy" and its metabolites is toxic to human SH-SY5Y differentiated cells at in vivo relevant concentrations. Archives of Toxicology, 2014, 88, 455-473.	4.2	45
49	Induction and activation of P-glycoprotein by dihydroxylated xanthenes protect against the cytotoxicity of the P-glycoprotein substrate paraquat. Archives of Toxicology, 2014, 88, 937-951.	4.2	36
50	Colchicine effect on P-glycoprotein expression and activity: In silico and in vitro studies. Chemico-Biological Interactions, 2014, 218, 50-62.	4.0	33
51	Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells. Toxicology Letters, 2013, 217, 34-41.	0.8	23
52	Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin. Toxicology Letters, 2013, 220, 259-266.	0.8	26
53	Development of Novel Rifampicin-Derived P-Glycoprotein Activators/Inducers. Synthesis, In Silico Analysis and Application in the RBE4 Cell Model, Using Paraquat as Substrate. PLoS ONE, 2013, 8, e74425.	2.5	23
54	Immortalized rat brain endothelial cells are highly resistant to paraquat toxic effect. Toxicology Letters, 2012, 211, S175.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes. <i>British Journal of Pharmacology</i> , 2012, 165, 1017-1033.	5.4	51
56	Cocaine-induced kidney toxicity: an in vitro study using primary cultured human proximal tubular epithelial cells. <i>Archives of Toxicology</i> , 2012, 86, 249-261.	4.2	43
57	P-glycoprotein induction by hypericin protects Caco-2 cells against paraquat toxicity. <i>Toxicology Letters</i> , 2011, 205, S93-S94.	0.8	2
58	P-glycoprotein activity assessment in rat brain endothelial cells – A search for new rifampicin-derived p-glycoprotein inducers. <i>Toxicology Letters</i> , 2011, 205, S94-S95.	0.8	0
59	In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. <i>Archives of Toxicology</i> , 2011, 85, 315-326.	4.2	51
60	Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound. <i>Colloids and Surfaces B: Biointerfaces</i> , 2011, 86, 158-165.	5.0	222
61	P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2011, 79A, 912-919.	1.5	26
62	Development and validation of a GC/IT-MS method for simultaneous quantitation of para and meta-synephrine in biological samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 52, 721-726.	2.8	26
63	First Report on <i>Cydonia oblonga</i> Miller Anticancer Potential: Differential Antiproliferative Effect against Human Kidney and Colon Cancer Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 3366-3370.	5.2	89
64	Human cancer cell antiproliferative and antioxidant activities of <i>Juglans regia</i> L.. <i>Food and Chemical Toxicology</i> , 2010, 48, 441-447.	3.6	243
65	The paraquat-induced toxicity is reversed with the co-exposure to doxorubicin in Caco-2 cells. <i>Toxicology Letters</i> , 2010, 196, S110.	0.8	0
66	Adrenaline in pro-oxidant conditions elicits intracellular survival pathways in isolated rat cardiomyocytes. <i>Toxicology</i> , 2009, 257, 70-79.	4.2	35
67	Adrenaline and reactive oxygen species elicit proteome and energetic metabolism modifications in freshly isolated rat cardiomyocytes. <i>Toxicology</i> , 2009, 260, 84-96.	4.2	30
68	Chronic exposure to ethanol exacerbates MDMA-induced hyperthermia and exposes liver to severe MDMA-induced toxicity in CD1 mice. <i>Toxicology</i> , 2008, 252, 64-71.	4.2	40
69	Synergistic toxicity of ethanol and MDMA towards primary cultured rat hepatocytes. <i>Toxicology</i> , 2008, 254, 42-50.	4.2	27
70	Effect of P-Glycoprotein inducers on its expression and activity in Caco-2 cells. <i>Toxicology Letters</i> , 2008, 180, S116.	0.8	0
71	Oxidation Process of Adrenaline in Freshly Isolated Rat Cardiomyocytes: Formation of Adrenochrome, Quinoproteins, and GSH Adduct. <i>Chemical Research in Toxicology</i> , 2007, 20, 1183-1191.	3.3	68
72	Evaluation of GSH adducts of adrenaline in biological samples. <i>Biomedical Chromatography</i> , 2007, 21, 670-679.	1.7	12

#	ARTICLE	IF	CITATIONS
73	Validation of a HPLC-ECD method for the detection of adrenaline-GSH adducts in biological samples. Toxicology Letters, 2006, 164, S132.	0.8	0
74	Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (â€œecstasyâ€œ) cytotoxicity. Toxicology Letters, 2006, 164, S295-S296.	0.8	0
75	Validation of a HPLC-ECD method for the quantification of the highly reactive metabolite of ecstasy, N-methyl-1±-methyldopamine, in human serum. Toxicology Letters, 2006, 164, S309.	0.8	0
76	Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (â€œEcstasyâ€œ™) cytotoxicity. Pharmacogenetics and Genomics, 2006, 16, 789-799.	1.5	44